Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

Valeant Pharmaceuticals International,Inc.
Posted on: 15 May 18
Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference

PR Newswire

LAVAL, Quebec, May 15, 2018

LAVAL, Quebec, May 15, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays High Yield Bond and Syndicated Loan Conference in Colorado Springs, Colo. on May 22, 2018 at 10:10 a.m. MDT (12:10 p.m. EDT).

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at:

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

Media Contact:

Media Contact:

Arthur Shannon   

Lainie Keller

(514) 856-3855            

(908) 927-0617

(877) 281-6642 (toll free)   



View original content with multimedia:

SOURCE Valeant Pharmaceuticals International, Inc.

PR Newswire

Last updated on: 15/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.